Literature DB >> 27403092

Parvovirus B19 Passive Transmission by Transfusion of Intercept® Blood System-Treated Platelet Concentrate.

Peter Gowland1, Stefano Fontana1, Martin Stolz1, Nicola Andina2, Christoph Niederhauser1.   

Abstract

BACKGROUND: Pathogen reduction methods for blood components are effective for a large number of viruses though less against small, non-enveloped viruses such as Parvovirus B19 (B19V). This article describes the passive transmission by transfusion of two B19V-contaminated pooled platelet concentrates (PCs) which were treated with the Intercept® blood pathogen reduction system. CASE REPORTS: Two transfusion cases of B19V-contaminated Intercept-treated pooled PCs were described. Due to the analysis delay, the PCs were already transfused. The viral content of each donation was 4.87 × 10(10) IU/ml in case 1and 1.46 × 10(8) IU/ml in case 2. B19V (52 IU/ml) was detected in the recipient of the case 1 PC, whereas no virus could be detected in the case 2 PC recipient. A B19V IgM response and a transient boost of the underlying B19V IgG immune status and was observed in recipient 1. Recipient of the case 2 PC remained B19V IgG- and IgM-negative. B19V DNA sequence and phylogenetic analysis revealed a 100% homology between donor and recipient.
CONCLUSION: This report describes passive B19V transmission by a PC with very high B19 viral load which elicited a transient boost of the B19V immunity, but not by a PC with a lower B19V content, suggesting that there is a B19 viral load threshold value at which B19V inactivation is exceeded.

Entities:  

Keywords:  Parvovirus B19; Pathogen inactivation; Pathogen reduction; Platelet transfusion; Transfusion-associated infections

Year:  2016        PMID: 27403092      PMCID: PMC4924464          DOI: 10.1159/000445195

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  25 in total

Review 1.  Parvovirus B19.

Authors:  Neal S Young; Kevin E Brown
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

2.  The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals.

Authors:  Sean Doyle; Amanda Corcoran
Journal:  J Infect Dis       Date:  2006-06-09       Impact factor: 5.226

Review 3.  Human parvovirus B19 and blood products.

Authors:  C Prowse; C A Ludlam; P L Yap
Journal:  Vox Sang       Date:  1997       Impact factor: 2.144

Review 4.  Component pathogen inactivation: a critical review.

Authors:  C V Prowse
Journal:  Vox Sang       Date:  2012-11-08       Impact factor: 2.144

5.  Parvovirus B19 transmission by heat-treated clotting factor concentrates.

Authors:  Johannes Blümel; Ivo Schmidt; Wolfgang Effenberger; Holger Seitz; Hannelore Willkommen; Hans Herrmann Brackmann; Johannes Löwer; Anna Maria Eis-Hübinger
Journal:  Transfusion       Date:  2002-11       Impact factor: 3.157

6.  Identification and characterization of persistent human erythrovirus infection in blood donor samples.

Authors:  Daniel Candotti; Nermin Etiz; Armen Parsyan; Jean-Pierre Allain
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples.

Authors:  Mei-Ying W Yu; Harvey J Alter; Maria Luisa A Virata-Theimer; Yansheng Geng; Li Ma; Cathy A Schechterly; Camilla A Colvin; Naomi L C Luban
Journal:  Transfusion       Date:  2010-02-12       Impact factor: 3.157

8.  Epidemiology of high-level parvovirus B19 viraemia among Dutch blood donors, 2003-2009.

Authors:  K Kooistra; H J Mesman; M de Waal; M H G M Koppelman; H L Zaaijer
Journal:  Vox Sang       Date:  2010-10-15       Impact factor: 2.144

9.  Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.

Authors:  Lynette Sawyer; Deborah Hanson; Grace Castro; William Luckett; Thomas W Dubensky; Adonis Stassinopoulos
Journal:  Transfusion       Date:  2007-06       Impact factor: 3.157

10.  Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.

Authors:  Lily Lin; Carl V Hanson; Harvey J Alter; Valérie Jauvin; Kristen A Bernard; Krishna K Murthy; Peyton Metzel; Laurence Corash
Journal:  Transfusion       Date:  2005-04       Impact factor: 3.157

View more
  3 in total

Review 1.  Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Authors:  Giovanni Di Minno; David Navarro; Carlo Federico Perno; Mariana Canaro; Lutz Gürtler; James W Ironside; Hermann Eichler; Andreas Tiede
Journal:  Ann Hematol       Date:  2017-06-18       Impact factor: 3.673

Review 2.  Parvovirus B19: What Is the Relevance in Transfusion Medicine?

Authors:  David Juhl; Holger Hennig
Journal:  Front Med (Lausanne)       Date:  2018-02-01

Review 3.  Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets.

Authors:  Peter Schubert; Lacey Johnson; Denese C Marks; Dana V Devine
Journal:  Front Med (Lausanne)       Date:  2018-05-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.